The Intracellular Pathogen Response (IPR) was identified as a common transcriptional response to multiple natural intracellular pathogens in C. elegans. These pathogens include species in a phylum of eukaryotic intracellular pathogens called Microsporidia, which are the most common cause of infection for C. elegans in the wild. IPR genes are distinct from those induced by heat shock and other stressors. Many of these IPR genes encode predicted components of the ubiquitylation system. Functional insights for the IPR came from analysis of
pals-22, a gene of unknown biochemical function, which suppresses the IPR.
pals-22 mutants have upregulated IPR gene expression, increased thermotolerance and pathogen resistance. Several components of a newly identified cullin-RING ubiquitin ligase mediate the increased thermotolerance of
pals-22 mutants1, but we know very little about how the IPR promotes pathogen resistance. Furthermore, we know little about how the IPR is regulated, although it appears to have dramatic effects on host physiology. To identify new regulators of the IPR, we performed a forward mutagenesis screen to identify mutants that display IPR activation in the absence of infection. From this screen, we identified K02D7.1 as a novel suppressor of the IPR. K02D7.1 is the C. elegans homolog of the vertebrate purine nucleosidase phosphorylase, which when mutated in humans leads to severe combined immunodeficiency due to aberrant T-cell death. K02D7.1 funtions in the purine degradation pathway and is required for generating free purine bases that are then converted into purine nucleotides by the purine salvage pathway. We found that K02D7.1 mutants display increased pathogen resistance against microsporidia. However, unlike
pals-22 mutants, K02D7.1 mutants do not display increased thermotolerance. By qPCR, we have determined that loss of K02D7.1 results in up-regulation of a subset of IPR genes but, interestingly, not the ubiquitin ligase genes required for increased thermotolerance observed in
pals-22 mutants1. We are currently investigating how specific metabolites in the purine degradation pathway regulate transcription of IPR genes, which may provide insight into how immunodeficiencies in humans are regulated by purine metabolism. 1. Panek et al, bioRXiv, 2019